Evaxion Biotech recently announced that it has selected the sexually transmitted disease gonorrhea as the second target for the EVX-B2 vaccine candidate, which is based on the EDEN technology platform. Preliminary preclinical results have shown that the AI platform EDEN has demonstrated the ability to identify two promising protective antigens based on very encouraging results. This suggests that EVX-B2 will be able to produce antibodies against this bacterial infection – minimizing the risk of infection, which affects over one million annually in the US.  Evaxion Biotech thus continues to build on its existing strong pipeline, which is an essential element of our investment case, which can be seen here.

Evaxion Biotech is a Danish biotherapeutics company listed in the US that uses AI-based platforms to develop immunotherapies for the treatment of cancer (the PIONEER platform) and infectious diseases, including bacterial (the EDEN platform) and viral (the RAVEN platform). Promising data from the two ongoing clinical programmes EVX-01 (treatment of metastatic melanoma) and EVX-02 (treatment of adjuvant melanoma) will, in our view, pave the way for further catalysts in the near term. We see several benefits from the use of AI-based platforms, which we believe could expand the use of immunotherapies into additional disease areas that we believe will add further value.